Trial Profile
A Multicenter, Single Arm Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Intolerant to Prior Tyrosine Kinase Inhibitors (TKIs).
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ENESTswift
- Sponsors Novartis
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 06 Dec 2016 Status changed from recruiting to discontinued due to low recruitment as per results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 03 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.